310 related articles for article (PubMed ID: 36059550)
1. Neoadjuvant immunotherapy and chemoimmunotherapy for stage II-III muscle invasive bladder cancer.
Chen H; Yang W; Xue X; Li Y; Jin Z; Ji Z
Front Immunol; 2022; 13():986359. PubMed ID: 36059550
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of neoadjuvant PD-1 inhibitors or PD-L1 inhibitors for muscle invasive bladder cancer: a systematic review and meta-analysis.
Huang S; Huang Y; Li C; Liang Y; Huang M; Luo R; Liang W
Front Immunol; 2023; 14():1332213. PubMed ID: 38264649
[TBL] [Abstract][Full Text] [Related]
3. Adverse events of neoadjuvant combination immunotherapy for resectable cancer patients: a systematic review and meta-analysis.
Feng Y; Guo K; Jin H; Jiang J; Wang M; Lin S
Front Immunol; 2023; 14():1269067. PubMed ID: 38250059
[TBL] [Abstract][Full Text] [Related]
4. Neoadjuvant immunotherapy or chemoimmunotherapy in non-small cell lung cancer: a systematic review and meta-analysis.
Jiang J; Wang Y; Gao Y; Sugimura H; Minervini F; Uchino J; Halmos B; Yendamuri S; Velotta JB; Li M
Transl Lung Cancer Res; 2022 Feb; 11(2):277-294. PubMed ID: 35280319
[TBL] [Abstract][Full Text] [Related]
5. A Network Comparison on Safety Profiling of Immune Checkpoint Inhibitors in Advanced Lung Cancer.
Yan YD; Cui JJ; Fu J; Su YJ; Chen XY; Gu ZC; Lin HW
Front Immunol; 2021; 12():760737. PubMed ID: 34925331
[TBL] [Abstract][Full Text] [Related]
6. Spatial Relationships in the Tumor Microenvironment Demonstrate Association with Pathologic Response to Neoadjuvant Chemoimmunotherapy in Muscle-invasive Bladder Cancer.
Beckabir W; Wobker SE; Damrauer JS; Midkiff B; De la Cruz G; Makarov V; Flick L; Woodcock MG; Grivas P; Bjurlin MA; Harrison MR; Vincent BG; Rose TL; Gupta S; Kim WY; Milowsky MI
Eur Urol; 2024 Mar; 85(3):242-253. PubMed ID: 38092611
[TBL] [Abstract][Full Text] [Related]
7. A systematic review and meta-analysis of neoadjuvant chemoimmunotherapy in stage III non-small cell lung cancer.
Liu W; Zhang T; Zhang Q; Li L; Xu C
BMC Pulm Med; 2022 Dec; 22(1):490. PubMed ID: 36582007
[TBL] [Abstract][Full Text] [Related]
8. Neoadjuvant and adjuvant treatments in muscle-invasive bladder cancer: Where are we?
Osanto S; Álvarez Gómez de Segura C
Arch Esp Urol; 2020 Dec; 73(10):971-985. PubMed ID: 33269716
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of neoadjuvant immunotherapy protocols and cycles for non-small cell lung cancer: a systematic review and meta-analysis.
Wang H; Liang S; Yu Y; Han Y
Front Oncol; 2024; 14():1276549. PubMed ID: 38292925
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of neoadjuvant immunotherapy in resectable gastric/gastroesophageal junction tumors: a meta-analysis and systematic review.
Wang J; Tong T; Zhang G; Jin C; Guo H; Liu X; Zhang Z; Li J; Zhao Y
Front Immunol; 2024; 15():1339757. PubMed ID: 38352873
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of neoadjuvant immunotherapy combined with chemoradiotherapy or chemotherapy in esophageal cancer: A systematic review and meta-analysis.
Liu Y; Bao Y; Yang X; Sun S; Yuan M; Ma Z; Zhang W; Zhai Y; Wang Y; Men Y; Qin J; Xue L; Wang J; Hui Z
Front Immunol; 2023; 14():1117448. PubMed ID: 36761760
[TBL] [Abstract][Full Text] [Related]
12. Comparison of neoadjuvant immunotherapy versus routine neoadjuvant therapy for patients with locally advanced esophageal cancer: A systematic review and meta-analysis.
Qin H; Liu F; Zhang Y; Liang Y; Mi Y; Yu F; Xu H; Li K; Lin C; Li L; Tian Z; Wang L
Front Immunol; 2023; 14():1108213. PubMed ID: 37033991
[TBL] [Abstract][Full Text] [Related]
13. Immune Checkpoint Inhibitors in the Treatment of Patients With Cancer and Preexisting Psoriasis: A Systematic Review and Meta-Analysis of Observational Studies.
Yu Y; Zhou Y; Zhang X; Tan K; Zheng J; Li J; Cui H
Front Oncol; 2022; 12():934093. PubMed ID: 35912183
[TBL] [Abstract][Full Text] [Related]
14. The efficacy and safety of neoadjuvant immunotherapy in resectable locally advanced esophageal squamous cell carcinoma: A systematic review and meta-analysis.
He W; Wang C; Li C; Nie X; Li H; Li J; Zhao N; Chen H; Miao X; Han Y; Peng L; Leng X
Front Immunol; 2023; 14():1118902. PubMed ID: 36875107
[TBL] [Abstract][Full Text] [Related]
15. Neoadjuvant immune checkpoint inhibitors in resectable non-small-cell lung cancer: a systematic review.
Ulas EB; Dickhoff C; Schneiders FL; Senan S; Bahce I
ESMO Open; 2021 Oct; 6(5):100244. PubMed ID: 34479033
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and Safety of Neoadjuvant Chemoimmunotherapy in Resectable Esophageal Squamous Cell Carcinoma: A Meta-analysis.
Xu J; Yan C; Li Z; Cao Y; Duan H; Ke S
Ann Surg Oncol; 2023 Mar; 30(3):1597-1613. PubMed ID: 36380254
[TBL] [Abstract][Full Text] [Related]
17. Analysis of treatment-related adverse events and wound complications of surgical resection after neoadjuvant chemoimmunotherapy for non-small cell lung cancer.
Li Y; Hu X; Zhang R; Wu N; Xia Q; Gu P
Int Wound J; 2024 Mar; 21(3):e14831. PubMed ID: 38484730
[TBL] [Abstract][Full Text] [Related]
18. Adverse Events of Immune Checkpoint Inhibitor-Based Therapies for Unresectable Hepatocellular Carcinoma in Prospective Clinical Trials: A Systematic Review and Meta-Analysis.
Zhang Y; Wang M; Chen Q; Deng Y; Chen J; Dai Y; Luo S; Xu J; Zhao H; Cai J
Liver Cancer; 2023 Dec; 12(6):521-538. PubMed ID: 38476294
[TBL] [Abstract][Full Text] [Related]
19. Safety of Neoadjuvant Immunotherapy in Resectable Cancers: A Meta-Analysis.
Xu J; Wu Y; Xu Y; Qiu Y; Li X; Song Y; Zhang L
Front Immunol; 2022; 13():802672. PubMed ID: 35173721
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of Clinical and Safety Outcomes of Neoadjuvant Immunotherapy Combined With Chemotherapy for Patients With Resectable Esophageal Cancer: A Systematic Review and Meta-analysis.
Ge F; Huo Z; Cai X; Hu Q; Chen W; Lin G; Zhong R; You Z; Wang R; Lu Y; Wang R; Huang Q; Zhang H; Song A; Li C; Wen Y; Jiang Y; Liang H; He J; Liang W; Liu J
JAMA Netw Open; 2022 Nov; 5(11):e2239778. PubMed ID: 36322089
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
